A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s10637-022-01262-2.pdf
Reference9 articles.
1. Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS et al (2015) Scientific Advances in Lung Cancer 2015. J Thorac Oncol 11(5):613–638. https://doi.org/10.1016/j.jtho.2016.03.012
2. Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, Sakao Y, Hida T, Yatabe Y (2016) Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 34(28):3383–3389. https://doi.org/10.1200/JCO.2015.65.8732
3. Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT et al (2018) Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer 122:67–71. https://doi.org/10.1016/j.lungcan.2018.05.020
4. Zeng J, Cui X, Cheng L, Chen Y, Du X, Sheng L (2020) Micropapillary pattern of stage IIIA-N(2) lung adenocarcinoma is a prognostic factor after adjuvant chemoradiotherapy. Future Oncol 16(36):3075–3084. https://doi.org/10.2217/fon-2020-0597
5. Cai C, Tang Y, Li Y, Chen Y, Tian P, Wang Y, Gong Y, Peng F, Zhang Y, Yu M et al (2021) Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients. Lung Cancer 152:104–108. https://doi.org/10.1016/j.lungcan.2020.12.018
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report;Investigational New Drugs;2022-08-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3